Identifying Patients who will benefit from long duration monoclonal antibody therapy for protection from COVID-19, Part 1
In this episode, Dr. Neil Skolnik and Dr. Amy Clouse discuss the use of long-acting monoclonal antibodies for COVID-19 pre-exposure prophylaxis. They explore the challenges and opportunities primary care clinicians and specialists face identifying appropriate patients to receive this treatment, with emphasis on patients who are immunocompromised and may not respond to vaccination.
This episode is part one of a three part series that examines the use of tixagevimab and cilgavimab for pre-exposure prophylaxis of COVID-19.
Funds for this activity have been provided by AstraZeneca.
This activity does not offer CME/CE credit
Faculty:
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Associate Director
Family Medicine Residency Program
Abington Jefferson Health
Philadelphia, PA
Amy Clouse, MD, FAAFP
Clinical Associate Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Associate Director
Family Medicine Residency Program
Abington Jefferson Health
Philadelphia, PA
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
